



### **Report Details**

Creation Date:31/05/2025Physician:Created By:RHHospital:

Received Date:31/05/25City:SYDNEYReviewed Date:Country:AUSTRALIA

#### **Patient Information**

Name: SM220753 NYHA:
Sex: STS Score:

Year Of Birth (Age):

**Comments:** Virtual valve for demonstration only, not a sizing or placement recommendation.


### Screenshots



ID 1	Гуре	Label	Value
<b>1</b> F	Polygon	Min. Ø	20.7 mm
		Max. Ø	32.2 mm
		Avg. Ø	26.5 mm
		Area	564.3 mm <sup>2</sup>
		Perimeter	87.7 mm

	LVOT	
SM220753	HALF	41% 0.92S CARDI 28/05/2025 41.0%
(	+	1 LGA
Series: 20 Image(s): 2561-3200 Slice Spacing: 0.2 mm Distance: 3.0 mm		


1	<b>D</b> Туре	Label	Value
•	<b>1</b> Polygo	n Min. Ø	22.4 mm
		Max. Ø	31.6 mm
		Avg. Ø	27.0 mm
		Area	537.8 mm <sup>2</sup>
		Perimeter	85.3 mm









41.0%




































## Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve System

## Annulus Sizing And Vascular Access

## Complete Range of Valve Sizes Expands the Treatable Patient Population











15.5 mm








SADIFN 3 valve show

	20 mm	23 mm	26 mm	29 mm
Inflation Volume	11 mL	17 mL	23 mL	33 mL
Area (CT)	273 - 345 mm <sup>2</sup>	338 - 430 mm <sup>2</sup>	430 - 546 mm <sup>2</sup>	540 - 683 mm <sup>2</sup>
Area-derived Diameter (CT)	18.6 - 21.0 mm	20.7 - 23.4 mm	23.4 - 26.4 mm	26.2 - 29.5 mm
Crimped Height*	21 mm	24.5 mm	27 mm	31 mm
Expanded Height	15.5 mm	18 mm	20 mm	22.5 mm
Foreshortening	5.5 mm	6.5 mm	7 mm	8.5 mm
Inner Skirt Height†	7.9 mm	9.3 mm	10.2 mm	11.6 mm
Outer Skirt Height - SAPIEN 3 THV	5.2 mm	6.6 mm	7.0 mm	8.1 mm
Outer Skirt Height - SAPIEN 3 Ultra THV*	7.3 mm	9.0 mm	9.7 mm	

Transcatheter heart valve size recommendations are based on native valve annulus size, as measured by transesophageal echocardiography (TEE) or computed tomography (CT). Patient anatomical factors and multiple imaging modalities should be considered during the transcatheter heart valve size selection. Risks associated with undersizing and oversizing should be carefully considered.

# Low Profile Access Demonstrates Significant Reduction in Major Vascular Complications<sup>‡</sup>



<sup>\*</sup>Rounded to the nearest 0.5 mm 
\*Measured at bottom of zig-zag

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized É logo, Edwards eSheath, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, eSheath, PARTNER, PARTNER II, SAPIEN, SAPIEN XT, SAPIEN 3, and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. PP--EU-1194 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon • Switzerland edwards.com



rible PARTNER II 53i Trial intermediate-risk SAPIEN 3 valve cohort (VARC II) versus the PARTNER IIA Trial intermediate-risk SAPIEN XT valve cohort (VARC I) 30-day unadjusted results.